Intuitive Surgical (ISRG), Fosun Pharma Establish JV Targeting Lung Cancer Diagnostic and Therapeutic Tools in China
- Futures dip as focus turns to Fed meeting
- BOJ hikes interest rates for first time in 17 years, to remain accommodative
- Buy the dip in US stocks in case of a 'rate shock' - Goldman
- Shares dip, yen slides as BOJ's landmark policy shift draws eyes
- Nvidia unveils Blackwell, AI chip 'to power this new industrial revolution'
- Canoo Inc. (GOEV) Provides Update on $62M Share Pre-Paid Advance Agreement
- Super Micro Computer (SMCI) Announces Proposed 2M Share Offering
- StoneCo (STNE) Tops Q4 EPS by 33c
- JOANN Inc (JOAN) Enters Agreement to Reduce Debt and Receive $132 Mln in New Capital
- Cisco Systems (CSCO) Completes Acquisition of Splunk (SPLK)
Intuitive Surgical and Fosun Pharma Establish Joint Venture to Research, Develop, Manufacture and Sell Lung Cancer Diagnostic and Therapeutic Tools in China
September 29, 2016 8:55 AM EDTSUNNYVALE, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ: ISRG) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fosun Pharma (600196.SH), (HKSE: 2196), today announced a joint venture to research, develop, manufacture and sell innovative, robotic-assisted catheter-based medical devices.
The joint venture between Intuitive Surgical, the global leader in robotic-assisted minimally invasive surgery, and Fosun Pharma, a leading healthcare group strategically comprising the complete value chain, will initially produce products targeting early diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms... More